International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer

The goal of this international, multicenter, prospective observational study is to improve prognostication and prediction of failure pattern for nasopharyngeal carcinoma (NPC), in order to provide more accurate guidance for personalized treatment decision. Firstly, we aim to improve the fundamental TNM staging system \[The American Joint Committee on Cancer(AJCC)/Union for International Cancer Control(UICC) TNM Version-Nine\] based on universally assessable anatomical parameters. Secondly, we aim to further refine prognostication for individual patients by integrating anatomical TNM parameters with non-anatomical factors and molecular biomarkers. In addition to the core group of participating centers from China (including Hong Kong) where NPC is most prevalent, the study will enrol patients from multiple countries/regions including those from non-endemic areas to provide global data. Patients treated with contemplary treatment methods during October 2025 to September 2026 will be recruited and they will be followed up for 5 years to generate detailed records for robust evaluation. Key Questions: * To achieve optimal improvement of anatomically based AJCC/UICC TNM Classification for global application * To achieve precise prediction of failure pattern for individual patients by integration of TNM system and non-anatomical prognostic factors/molecular biomarkers Recruited patients with confirmed histological diagnosis of NPC will undergo standard clinical evaluations and receive treatment per institutional guidelines. The anatomical extent of disease at presentation will be evaluated by experienced radiologists and oncologists. The patient will be followed up for 5 years and clinical outcome will be recorded for analyses on correlation with prognostic factors. This study will be another important milestone for NPC staging because firstly, this is the first time that the data are based on prospective data to ensure comprehensive coverage of all essential evidence; and secondly, this is the first time that centers from non-endemic countries/regions will also participate to ensure that the final recommendations are globally applicable. The findings will provide valuable evidence for the development of the AJCC/UICC TNM Version-Ten staging system and prognostic system to improve risk stratification for designing personalized treatment strategy, ultimately leading to improvement of patient outcome and patient selection for future research worldwide.

NCT Number	NCT07013461
Lead Sponsor	The University of Hong Kong-Shenzhen Hospital Collaborators: Fujian Cancer Hospital, Chinese Academy of Medical Sciences, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Sichuan Cancer Hospital and Research Institute, First Affiliated Hospital of Fujian Medical University, Queen Mary Hospital, Hong Kong, The Queen Elizabeth Hospital, Pamela Youde Nethersole Eastern Hospital, Princess Margaret Hospital, Hong Kong, United Christian Hospital, Prince of Wales Hospital, Shatin, Hong Kong, Fudan University, Hunan Cancer Hospital, National Cancer Centre, Singapore, Sun Yat-Sen University Cancer Center, Tuen Mun Hospital
Conditions	Nasopharyngeal Cancinoma (NPC)
Enrollment	5,000 participants
Start Date	2026-01-09
Primary Completion	2031-12-31 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-04